Dasatinib Side Effects

Reported Dasatinib side effects

Dasatinib has a substantial and well-characterized side effect profile from extensive oncologic use. Intermittent senolytic dosing reduces but does not eliminate these risks. Common Side Effects in Chronic Oncologic Dosing (for context): Thrombocytopenia (>20% of patients, dose-related); neutropenia (15-25%); anemia (10-20%); fluid retention including pleural effusion (10-30%, higher with BID vs QD dosing), peripheral edema, ascites; diarrhea (20-30%); headache (20-30%); fatigue (20-30%); nausea (15-25%); rash (15-25%); musculoskeletal pain; elevated liver enzymes (5-15%). Serious Side Effects in Oncologic Dosing: Severe myelosuppression requiring dose interruption/reduction; pulmonary arterial hypertension (rare, potentially irreversible, requires monitoring); pleural effusion requiring thoracentesis; GI bleeding (uncommon but notable); QTc prolongation and rare torsades; rare severe skin reactions (Stevens-Johnson syndrome). Side Effects in Senolytic Intermittent Dosing: Lower absolute incidence but still notable. Most commonly reported in pilot trials and off-label use: Mild-moderate fatigue (30-50% of single-pulse exposures); GI upset — nausea, loose stools, abdominal discomfort (20-30%); headache (10-20%); transient myalgia/arthralgia (10-15%); easy bruising or minor bleeding (platelet function impairment; variable); transient fluid retention/edema (rare). Rare But Reported in Senolytic Dosing: GI bleeding (hematochezia, melena, hematemesis) — this is a notable concern given dasatinib's platelet inhibition; cases have been reported even in intermittent pulsed dosing. Pleural effusion — rare but reported with intermittent dosing. Atrial fibrillation — rare reports. Significant transaminase elevations. Severe headache with intracranial bleeding concerns. Bleeding Risk Mechanism: Dasatinib's SRC kinase inhibition affects platelet function independent of platelet count. Platelets express SRC family kinases involved in ADP/thromboxane/collagen-receptor signaling. Dasatinib-exposed platelets have impaired aggregation even at normal platelet counts. Intermittent dosing allows platelet function recovery between cycles (~2-4 weeks for full restoration) but within-cycle and shortly post-cycle bleeding risk is elevated. Drug Interactions: Extensive. Strong CYP3A4 Inhibitors (AVOID or SUBSTANTIAL DOSE REDUCTION): ketoconazole, itraconazole, voriconazole, posaconazole (antifungals); clarithromycin, erythromycin, telithromycin (antibiotics); ritonavir, cobicistat, lopinavir, nelfinavir (HIV antivirals); nefazodone; grapefruit juice >1 glass/day; amiodarone (longer half-life interaction). Moderate CYP3A4 Inhibitors (CAUTION/DOSE ADJUSTMENT): diltiazem, verapamil (CCBs); fluconazole; aprepitant; amiodarone (acute); imatinib; some statins. Strong CYP3A4 Inducers (AVOID): rifampin, rifabutin; phenytoin, carbamazepine, phenobarbital (anticonvulsants); St. John's Wort; enzalutamide, apalutamide; modafinil (moderate inducer); efavirenz, nevirapine. Gastric pH Agents (Critical Interaction): PPIs (omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, dexlansoprazole) — dramatically reduce dasatinib absorption with chronic use; avoid if possible; if required, use separation timing of 12+ hours (PPI morning, dasatinib evening). H2 blockers (famotidine, cimetidine, ranitidine, nizatidine) — moderate reduction; separate dasatinib from H2 blocker by at least 2 hours (ideally 10 hours). Antacids (calcium carbonate, magnesium hydroxide, aluminum hydroxide) — moderate reduction; separate by 2 hours. Anticoagulants: Warfarin — additive bleeding risk with platelet dysfunction; INR monitoring more frequent during dasatinib exposure windows. DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) — additive bleeding risk; consider holding during pulsed dosing. Antiplatelet Agents: Aspirin, clopidogrel, prasugrel, ticagrelor — additive antiplatelet effect; notable bleeding risk with combination; careful risk-benefit decision required. Some protocols hold antiplatelet during pulsed dosing. NSAIDs: Additive bleeding risk via GI effects and platelet effects; minimize NSAID use during and near dasatinib pulses. SSRIs/SNRIs: Mild additive bleeding risk; generally not contraindicated. Other TKIs: Combining dasatinib with other TKIs is generally avoided. Cardiac Medications: QTc-prolonging agents — additive QTc risk; monitor ECG. Amiodarone — complex interaction including QTc additive effect plus CYP3A4 inhibition. Immunosuppressants: Tacrolimus, cyclosporine, sirolimus, everolimus — complex CYP3A4 interactions; avoid or monitor closely. Chemotherapy Agents: Additive toxicity in oncologic contexts; complex coordination for comprehensive treatment plans. Statins: CYP3A4-metabolized statins (simvastatin, atorvastatin, lovastatin) — potential increased exposure; prefer rosuvastatin or pravastatin during dasatinib exposure windows. Food Interactions: Grapefruit juice regular consumption — avoid during dasatinib exposure. Food does not substantially affect dasatinib absorption (can take with or without food). Alcohol: Minimize during dasatinib exposure windows due to additive GI irritation and bleeding risk. Moderate alcohol between cycles acceptable. Pregnancy: Category D (not recommended in pregnancy). Contraception required for women of reproductive potential during treatment and for appropriate interval after last dose. Breastfeeding: Do not breastfeed during dasatinib treatment. Pediatric Use: FDA-approved for pediatric Ph+ ALL and chronic-phase CML; pediatric senolytic use is NOT established and not appropriate outside specific clinical trials. Elderly: Standard dosing applies; watch for drug interactions given polypharmacy. Renal Impairment: No specific dose adjustment in mild-moderate renal impairment; data limited in severe. Hepatic Impairment: Use caution; dose adjustment may be needed. Surgical Considerations: Hold dasatinib at least 1 week before elective surgery; do not resume until bleeding risk acceptable (typically 1-2 weeks post-op). Emergency surgery: consider platelet transfusion if significant bleeding. Myelosuppression Monitoring: Even in intermittent senolytic dosing, baseline CBC before first pulse is essential. Repeat CBC 1 week after pulse is reasonable to identify unexpected cytopenias. Liver Function Monitoring: Baseline and periodic LFTs (ALT, AST, alkaline phosphatase, bilirubin). Hepatitis B reactivation has been reported with dasatinib; HBV screening in at-risk populations. Cardiac Monitoring: Baseline ECG for QTc; consider periodic ECG with chronic exposure. Echocardiogram for pulmonary pressure assessment with long-term or high-exposure dosing. Product Quality/Source: Dasatinib is prescription-only; legitimate sources are pharmacies with prescription (either brand Sprycel or generic dasatinib now available in most markets). Research-chemical-sourced dasatinib lacks quality assurance and is legally problematic in most jurisdictions. DO NOT purchase from unregulated sources. Storage: Room temperature, protected from humidity and light. Original container. Discontinuation in Adverse Event: Dasatinib should be held for any significant adverse event (bleeding, severe GI effects, cardiac symptoms, respiratory symptoms). Resumption requires clinical judgment and typically involves risk-benefit reassessment. Overall Safety Assessment: Dasatinib is a potent TKI with substantial adverse effect potential. Intermittent senolytic dosing has better safety profile than chronic oncologic dosing, but it is NOT a benign intervention. Appropriate for: physician-supervised use with monitoring; baseline and periodic labs; clear risk-benefit rationale; coordination with all prescribers. Not appropriate for: casual self-experimentation; use without baseline/monitoring labs; use in patients with bleeding diathesis, active cardiac or pulmonary disease, or complex medication regimens without careful drug interaction review.

When to continue, reduce, or stop Dasatinib

Dasatinib contraindications

Dasatinib has significant contraindications and extensive drug interactions that substantially limit appropriate use. Absolute Contraindications: Known hypersensitivity to dasatinib or tablet excipients (rare); Active severe bleeding or coagulopathy; Severe uncontrolled cardiac arrhythmia (particularly QTc-prolonging conditions); Active severe infection (relative — may proceed after resolution); Pregnancy (Category D; contraception required during use); Breastfeeding. Strong Relative Contraindications (Essentially Exclude Use Without Specialist Guidance): Active bleeding disorder (hemophilia, severe thrombocytopenia, significant platelet dysfunction); Recent major bleeding event (GI bleed, intracranial hemorrhage, etc.); Uncontrolled cardiovascular disease (recent MI, unstable angina, severe heart failure); Pre-existing pulmonary arterial hypertension; Severe hepatic impairment (Child-Pugh C); Severe chronic kidney disease on dialysis (data limited); Active hepatitis B infection (risk of reactivation); Long QT syndrome or significant baseline QTc prolongation; History of severe dasatinib-associated adverse events; Severe platelet dysfunction from other causes (uremia, severe liver disease, etc.). Relative Contraindications (Use With Caution and Specific Precautions): Controlled bleeding risk (on antiplatelet/anticoagulants — requires bleeding risk discussion and possibly temporary holding); Mild-moderate cardiovascular disease; Mild-moderate pulmonary disease; History of pleural effusion (regardless of cause); History of GI bleeding or peptic ulcer; Chronic PPI use (impaired absorption); Multiple medications with significant drug interactions; Elderly (>75) with multiple comorbidities; Pregnancy planning (stop before conception attempts); Active cancer not related to dasatinib indication (complex interaction potential with other cancer treatments); Elective surgery planned within 2-3 weeks. Drug Interactions — COMPREHENSIVE LIST: Strong CYP3A4 Inhibitors (AVOID OR DOSE REDUCE): Antifungals: ketoconazole, itraconazole, posaconazole, voriconazole. Macrolide antibiotics: clarithromycin, telithromycin, erythromycin. HIV/HCV antivirals: ritonavir, cobicistat, lopinavir, nelfinavir, indinavir, saquinavir; elbasvir, grazoprevir (some combinations). Other: nefazodone, conivaptan; grapefruit juice regular consumption (>1 glass/day); Seville orange; pomelo; star fruit. If strong CYP3A4 inhibitor cannot be held, reduce dasatinib to 20-40 mg equivalent or use alternative senolytic. Moderate CYP3A4 Inhibitors (CAUTION/DOSE ADJUSTMENT): Calcium channel blockers: diltiazem, verapamil. Antifungals: fluconazole (mild-moderate), isavuconazole. Antibiotics: some quinolones (ciprofloxacin mild). Antiemetics: aprepitant (chemotherapy antiemetic; moderate inhibitor). Statins (as CYP3A4 inhibitors rather than substrates): atorvastatin (mild), lovastatin (mild-moderate). Hormone replacement: some progesterones. CBD: high-dose cannabidiol is moderate CYP3A4 inhibitor; clinically relevant at medical-grade doses. Strong CYP3A4 Inducers (AVOID): Antimicrobials: rifampin, rifabutin, rifapentine. Anticonvulsants: phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine (moderate). Antiviral: efavirenz, etravirine, nevirapine. Tuberculosis treatment: isoniazid/rifampin combinations. Herbal: St. John's Wort. Other: enzalutamide, apalutamide, modafinil (moderate). If strong CYP3A4 inducer cannot be held, efficacy will be substantially reduced; consider alternative senolytic (fisetin). Gastric pH Modifiers (CRITICAL ABSORPTION INTERACTION): PPIs (ALL): omeprazole, esomeprazole, pantoprazole, lansoprazole, rabeprazole, dexlansoprazole. Chronic PPI dramatically reduces dasatinib absorption (possibly >40% reduction). Strategy: hold PPI during pulse days; if cannot hold (severe reflux, active ulcer), use H2 blocker alternative with timing separation, or use alternative senolytic (fisetin). H2 Blockers: famotidine, cimetidine, ranitidine, nizatidine. Moderate absorption effect. Strategy: dasatinib 2-10 hours before H2 blocker. Antacids: calcium carbonate, magnesium hydroxide, aluminum hydroxide, sodium bicarbonate. Moderate effect. Strategy: separate by 2 hours. Sucralfate: can affect absorption; separate by 2 hours. Bile acid sequestrants (cholestyramine, colestipol): separate by 4 hours. QTc-Prolonging Agents: Class Ia/Ic antiarrhythmics: quinidine, procainamide, disopyramide, flecainide, propafenone — additive QTc risk. Class III antiarrhythmics: amiodarone, sotalol, dofetilide, dronedarone, ibutilide — additive QTc risk plus amiodarone CYP3A4 inhibition. Antipsychotics: haloperidol, ziprasidone, quetiapine (modest), thioridazine, pimozide. Antidepressants: tricyclics (amitriptyline, imipramine, etc.), citalopram (moderate QTc effect), escitalopram. Macrolides (many — already listed as CYP3A4 inhibitors): also additive QTc. Fluoroquinolones: levofloxacin, moxifloxacin (more QTc), ciprofloxacin (less). Antiemetics: ondansetron, granisetron (mild). Others: methadone, pentamidine, some TCAs. Strategy: review ECG baseline; avoid combinations in patients with baseline QTc prolongation. Anticoagulants: Warfarin: additive bleeding risk; INR monitoring during dasatinib exposure; possible dose adjustment. DOACs: apixaban, rivaroxaban, dabigatran, edoxaban — additive bleeding risk; consider holding during pulse days if clinical situation allows. Heparins/LMWH: enoxaparin, dalteparin, fondaparinux, heparin — additive bleeding risk; avoid overlap when possible. Antiplatelet Agents: Aspirin (all doses including low-dose cardiovascular prophylaxis) — additive antiplatelet effect; bleeding risk consideration; some protocols hold 81 mg aspirin during pulse days. P2Y12 inhibitors: clopidogrel, prasugrel, ticagrelor — significant additive antiplatelet effect; bleeding risk; some protocols hold during pulse days. Dipyridamole, cilostazol — additive antiplatelet. NSAIDs: All NSAIDs (ibuprofen, naproxen, diclofenac, meloxicam, celecoxib, ketorolac, etc.) — additive bleeding and GI effects; hold during pulse days and avoid for at least 3 days post-pulse when possible. Acetaminophen acceptable as NSAID alternative. Other Kinase Inhibitors: Combination with other TKIs (imatinib, nilotinib, bosutinib, ponatinib, sunitinib, sorafenib, etc.) is generally avoided in senolytic contexts; may be relevant in complex oncology cases. Immunosuppressants: tacrolimus, cyclosporine, sirolimus, everolimus — CYP3A4 interactions; monitor drug levels; avoid combinations when possible. Hormone Replacement: estrogens, progestins — generally compatible; some modest CYP3A4 interactions. Contraceptives: oral contraceptives generally compatible; injectable contraceptives no interaction. Pregnancy Prevention: women of reproductive potential on dasatinib must use reliable contraception during treatment. Antidiabetic Agents: insulin, sulfonylureas, metformin, GLP-1 agonists, SGLT2 inhibitors — generally compatible; monitor glucose. Thyroid Hormone (Levothyroxine): generally compatible; some reports of thyroid dysfunction with dasatinib (monitor TFTs periodically). Psychiatric Medications: SSRIs, SNRIs — mild QTc considerations (particularly citalopram, escitalopram); additive bleeding risk with SSRIs; generally usable with monitoring. Pain Management: Opioids — generally compatible; fentanyl and some others CYP3A4 metabolized so exposure may be affected. Inhaled Medications: inhaled corticosteroids, bronchodilators — no significant interaction. Topical Medications: no significant systemic interactions. Herbal Interactions: St. John's Wort (CYP3A4 inducer) — avoid. Goldenseal (CYP3A4 inhibitor) — caution. Kava — avoid (hepatotoxicity). Ginkgo — additive bleeding. Garlic (high-dose) — additive bleeding. Ginger (high-dose) — additive bleeding. Ginseng — modest CYP3A4 effects; generally compatible. Milk thistle — generally compatible. Turmeric/Curcumin — compatible at typical supplemental doses; additive antiplatelet at high doses. Green tea extract (high dose) — potential CYP3A4 effects. Alcohol: Avoid during and for 24 hours after pulse days. Moderate consumption between cycles acceptable. Heavy drinking should be addressed regardless of dasatinib use. Tobacco: Not a direct pharmacokinetic interaction but smokers have increased cardiovascular and pulmonary risk that compounds dasatinib risks. Cannabis: High-dose CBD is CYP3A4 inhibitor (relevant); THC has less interaction but may have cardiac effects at high dose. Generally minimize during pulse days. Food: Grapefruit juice (avoid during pulse). Regular balanced meals acceptable. Take with or without food. Laboratory Test Effects: Dasatinib does not typically interfere with common laboratory assays. May affect thyroid function tests modestly with chronic use. Surgical Considerations: Hold dasatinib at least 1 week before elective surgery; longer (2-3 weeks) if possible given platelet function effects. Emergency surgery: consider platelet transfusion for significant bleeding; discuss with hematology for management. Dental Procedures: Hold dasatinib at least 1 week before invasive dental procedures (extractions, implants, deep cleaning with significant bleeding); routine cleaning without bleeding generally acceptable. Vaccinations: Live vaccines generally avoided during oncologic TKI therapy; intermittent senolytic dosing may be more permissive but timing considerations important (e.g., receive vaccines at least 2 weeks before or 2 weeks after pulse). Inactivated vaccines generally acceptable. Special Populations: Elderly (>65): Compatible with monitoring; higher comorbidity burden requires careful drug interaction review; dose reduction may be appropriate. Frail elderly (>80): Consider alternative senolytics (fisetin) given better safety profile. Renal Impairment: No specific dose adjustment for mild-moderate; limited data severe. Hepatic Impairment: Dose reduction for moderate; avoid for severe. Pregnancy: Contraindicated. Breastfeeding: Contraindicated. Pediatric Senolytic Use: NOT appropriate outside specific trials. Active Cancer: Oncologic coordination essential. Transplant Recipients: Immunosuppressant interactions; specialist coordination. HIV/HCV Patients: Antiretroviral interactions; specialist coordination. Regulatory Status: Prescription-only globally. Off-label senolytic use requires licensed physician prescription. Quality/Product: Use only pharmacy-sourced product with prescription; avoid research-chemical sources. Overdose: Rare in senolytic context given intermittent dosing. Management: supportive care; monitor for cytopenias, bleeding, fluid retention, cardiac symptoms; no specific antidote. Discontinuation: Can be stopped abruptly without withdrawal. Senescent cell burden gradually increases post-discontinuation. Symptoms Requiring Urgent Medical Attention: GI bleeding (melena, hematemesis, hematochezia); severe fatigue with pallor; shortness of breath; chest pain; severe headache with neurologic symptoms; prolonged/heavy bleeding; severe abdominal pain; edema with weight gain; jaundice; severe rash with systemic symptoms; fever suggesting infection. Final Assessment: Dasatinib has one of the most extensive drug interaction and safety consideration profiles of any intervention commonly used in longevity medicine. Appropriate use requires complete clinical partnership. For many patients, fisetin provides a substantially safer senolytic option that can be used OTC without the interaction complexity.

Why vendor quality drives Dasatinib side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Dasatinib side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .